NASDAQ: KRROKorro Bio Inc Stock
$12.49+0.46 (+3.82%)
Updated Jun 30, 2025
KRRO Price
$12.49
Fair Value Price
$1.03
Market Cap
$117.29M
52 Week Low
$10.29
52 Week High
$98.00
P/E
-1.32x
P/B
0.84x
P/S
33.89x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.82M
Earnings
-$87.41M
Gross Margin
100%
Operating Margin
-1,810.56%
Profit Margin
-1,813.1%
Debt to Equity
0.46
Operating Cash Flow
-$63M
Beta
1.14
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
KRRO Overview
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine KRRO's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important KRRO news, forecast changes, insider trades & much more!
KRRO News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KRRO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KRRO ($12.49) is overvalued by 1,115.86% relative to our estimate of its Fair Value price of $1.03 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
KRRO ($12.49) is not significantly undervalued (1,115.86%) relative to our estimate of its Fair Value price of $1.03 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
KRRO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KRRO due diligence checks available for Premium users.
Valuation
KRRO fair value
Fair Value of KRRO stock based on Discounted Cash Flow (DCF)
Price
$12.49
Fair Value
$1.03
Overvalued by
1,115.86%
KRRO ($12.49) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KRRO ($12.49) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KRRO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
KRRO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.32x
Industry
-123.86x
Market
32.47x
KRRO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.84x
Industry
4.44x
KRRO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KRRO's financial health
Profit margin
Revenue
$2.6M
Net Income
-$23.4M
Profit Margin
-917.1%
KRRO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
KRRO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$202.2M
Liabilities
$63.3M
Debt to equity
0.46
KRRO's short-term assets ($121.24M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KRRO's short-term assets ($121.24M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KRRO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
KRRO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$24.5M
Investing
$32.8M
Financing
$172.0k
KRRO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
KRRO vs Biotech Stocks
Korro Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.